Yan Hong Shang1, Yu Zhang2, Jing Hua Li3, Peng Li4, Xi Zhang5. 1. Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, P R China. 2. Department of internal Medicine, Baoding Children's Hospital, Baoding 071000, P R China. 3. Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, Baoding 071000, P R China. 4. Departments of Ultrasound, Affiliated Hospital of Hebei University, Baoding 071000, P R China. 5. Department of Radiation Oncology, Affiliated Hospital of Hebei University, 212 East Yuhua Road, Baoding 071000, Hebei, P R China.
Abstract
AIM: We conducted this meta-analysis to investigate the overall incidence and risk of endocrine complications in cancer patients treated with PD-1 inhibitors. METHODS: Pubmed, Embase and oncology conference proceedings were searched for relevant studies. RESULTS: In comparison with chemotherapy or everolimus or cetuximab control, PD-1 inhibitors significantly increased the risk of all grade hypothyroidism (relative risk: 6.38; 95% CI: 3.78-10.77; p < 0.001) and hyperthyroidism (relative risk: 5.08; 95% CI: 2.55-10.14; p < 0.001), but not for hypophysitis. When compared with ipilimumab control, the risk of all grade hyperthyroidism and hypothyroidism with PD-1 inhibitors monotherapy seemed to be higher than ipilimumab, while the risk of hypophysitis was lower than ipilimumab. CONCLUSION: Treatment with PD-1 inhibitors is associated with an increased risk of developing hypothyroidism and hyperthyroidism, but not for hypophysitis.
AIM: We conducted this meta-analysis to investigate the overall incidence and risk of endocrine complications in cancerpatients treated with PD-1 inhibitors. METHODS: Pubmed, Embase and oncology conference proceedings were searched for relevant studies. RESULTS: In comparison with chemotherapy or everolimus or cetuximab control, PD-1 inhibitors significantly increased the risk of all grade hypothyroidism (relative risk: 6.38; 95% CI: 3.78-10.77; p < 0.001) and hyperthyroidism (relative risk: 5.08; 95% CI: 2.55-10.14; p < 0.001), but not for hypophysitis. When compared with ipilimumab control, the risk of all grade hyperthyroidism and hypothyroidism with PD-1 inhibitors monotherapy seemed to be higher than ipilimumab, while the risk of hypophysitis was lower than ipilimumab. CONCLUSION: Treatment with PD-1 inhibitors is associated with an increased risk of developing hypothyroidism and hyperthyroidism, but not for hypophysitis.
Authors: Ester Simeone; Antonio M Grimaldi; Lucia Festino; Claudia Trojaniello; Maria G Vitale; Vito Vanella; Marco Palla; Paolo A Ascierto Journal: Melanoma Manag Date: 2019-11-08
Authors: Sofia España; Alejandra Pérez Montes de Oca; Montserrat Marques-Pamies; Marc Cucurull; Marta Domenech; José María Velarde; Isabel Salinas; Teresa Moran; Olatz Etxaniz Journal: Transl Lung Cancer Res Date: 2020-02